Market Synopsis of Global TMJ disorders Market
TMJ (temporomandibular joint and muscle) disorder is a medical condition which causes dysfunction and pain in the jaw joint and the muscles that control jaw movement. The medical condition is diagnosed more frequently in women than the men. According to the American Academy of Orofacial Pain, TMJ disorders may have more than one symptoms and causes. Some of the major symptoms of this disorder are aching facial pain, tenderness or pain in jaws, pain while chewing etc. TMJ disorders can occur if the joint's cartilage is damaged by arthritis or by a blow or other impact or the disk erodes or moves out of its proper alignment.
According to the recent study report published by the Market Research Future, global TMJ disorders industry is booming and expected to gain prominence over the forecast period. The market is projected to demonstrate a sound growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
The major drivers will be the increasing prevalence of TMJ disorder, rising healthcare expenditures and growing awareness for the oral health. According to the National Institute of Dental and Craniofacial Research in 2014, the prevalence of temporomandibular joint and muscle disorder (TMJD) was in between 5% to 12%. Moreover, according to the Centers for Medicare & Medicaid Services in 2016, the U.S. healthcare expenditure was about USD 3.3 trillion, which accounted for 17.9% of the total GDP within the same year.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4090
However, lack of awareness and low per capita healthcare expenditure in the middle and low income countries may restrain the market growth during the forecast period.
North America leads the TMJ Disorders market share owing to well-developed healthcare infrastructure and rising per capita healthcare expenditure. Following the same trends Europe holds the second largest market share. Asia Pacific is the fastest growing region for the market due to the presence of the developed economies like India and China within the region. According to the Indian Brand Equity Foundation in 2017, Indian healthcare sector is one of the fastest growing industries which is expected to advance at a CAGR of 22.87% during 2015-20 and reach USD 280 billion by 2020. However, Middle East and Africa holds the least market share in the global market. Presence of the stringent government policies and low per capita income in the African region restrains the market growth during the forecast period. On the other hand, Middle East leads the market of the Middle East & Africa region, due to the presence of developed economies like Kuwait and Qatar.
Global TMJ Disorders Market - Competitive Analysis
Characterized by the presence of several well-established and small players, the TMJ disorders market appears to be highly competitive and fragmented. International players are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Pfizer Inc. is a U.S. based biopharmaceutical company and plays a significant role in the TMJ disorders market. The company’s total revenue was about USD 52,824 million in 2016. Moreover, it was estimate that the company spent 14.9% of its total revenue in research and development which made the company to improve its position in the global market and enhance its product portfolio.
In August 2016, FDA approved Pfizer's TROXYCA ER extended-release capsules CII for pain management.
In March 2017, ALLERGAN announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURE XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Jubilant Cadista (US), Pfizer Inc. (US), and Sun Pharmaceutical Industries Ltd. (India) are some of the prominent players at the forefront of competition in the global TMJ disorders market and are profiled in MRFR Analysis. Global TMJ Disorders Market - Regional Analysis
Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/tmj-disorders-market-4090
No comments:
Post a Comment